Form 4: Sarepta Therapeutics Executive Louise Rodino-Klapac Reports Stock Transactions
SEC Form 4 Filing
Louise Rodino-Klapac, Head of R&D and CSO at Sarepta Therapeutics, reports the vesting of performance stock units and subsequent stock sales to cover tax obligations.
Summary
- On March 6, 2025, Louise Rodino-Klapac vested 17,500 shares from a performance stock unit (PSU) award granted on March 6, 2023.
- On March 7, 2025, 514 shares were sold at $103.7 per share to cover tax obligations related to the vesting of restricted stock units granted on March 6, 2023.
- An additional 7,990 shares were sold on March 7, 2025, at $103.7 per share to cover tax obligations related to the vesting of the PSUs.
- Following these transactions, Rodino-Klapac directly owns 74,318 shares of Sarepta Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment. It reflects routine compensation practices.
Industry Context
This Form 4 filing is a routine disclosure of stock transactions by a company insider, providing transparency to investors regarding the executive's holdings and transactions in the company's stock.
Stakeholder Impact
- The transactions provide transparency to shareholders regarding executive compensation and stock ownership.
Key Dates
| Date | Description |
|---|---|
| 03/06/2023 | Date of grant for the performance stock unit (PSU) award and restricted stock units. |
| 03/06/2025 | Date of vesting for 17,500 shares from the PSU award. |
| 03/07/2025 | Date of stock sales to cover tax obligations related to vesting of restricted stock units and PSUs. |
| 03/10/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.